Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Thermo Fisher Scientific Inc., profitability ratios (quarterly data)
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Thermo Fisher Scientific Inc.’s gross profit margin ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Thermo Fisher Scientific Inc.’s operating profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Thermo Fisher Scientific Inc.’s net profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Thermo Fisher Scientific Inc.’s ROE deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
ROA | A profitability ratio calculated as net income divided by total assets. | Thermo Fisher Scientific Inc.’s ROA deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Gross Profit Margin
Thermo Fisher Scientific Inc., gross profit margin calculation (quarterly data)
Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 31, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Oct 1, 2016 | Jul 2, 2016 | Apr 2, 2016 | Dec 31, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Gross profit | 4,331 | 3,377 | 2,740 | 3,035 | 2,763 | 2,823 | 2,707 | 2,924 | 2,615 | 2,738 | 2,580 | 2,669 | 2,300 | 2,283 | 2,193 | 2,279 | 2,054 | 2,079 | 1,958 | 2,108 | 1,883 | 1,942 | 1,823 | |||||||
Revenues | 8,521 | 6,917 | 6,230 | 6,829 | 6,272 | 6,316 | 6,125 | 6,507 | 5,920 | 6,078 | 5,853 | 6,047 | 5,116 | 4,990 | 4,765 | 4,953 | 4,491 | 4,535 | 4,295 | 4,653 | 4,123 | 4,271 | 3,919 | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Gross profit margin1 | 47.31% | 45.39% | 44.30% | 44.35% | 44.48% | 44.51% | 44.60% | 44.57% | 44.36% | 44.55% | 44.68% | 45.15% | 45.67% | 45.88% | 45.90% | 45.80% | 45.62% | 45.60% | 45.51% | 45.72% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 45.15% | 46.24% | 47.78% | 47.94% | 47.42% | 47.28% | 45.04% | 45.44% | 45.60% | 46.00% | 49.30% | 49.14% | 48.86% | 48.57% | 48.59% | 47.99% | 47.66% | 44.92% | 45.09% | 45.66% | — | — | — | |||||||
Boston Scientific Corp. | 67.20% | 68.26% | 70.41% | 70.98% | 71.20% | 71.33% | 71.12% | 71.37% | 71.48% | 71.35% | 71.78% | 71.34% | 71.27% | 71.38% | 70.86% | 71.09% | 70.88% | 70.78% | 70.99% | 70.94% | — | — | — | |||||||
Danaher Corp. | 55.04% | 55.28% | 55.85% | 55.74% | 55.61% | 55.53% | 55.71% | 55.83% | 56.03% | 56.18% | 55.80% | 55.61% | 55.27% | 55.09% | 55.36% | 55.29% | 54.16% | 53.47% | 52.86% | 52.34% | — | — | — | |||||||
Edwards Lifesciences Corp. | 75.50% | 74.97% | 74.40% | 74.37% | 74.40% | 74.89% | 75.46% | 74.77% | 74.13% | 73.84% | 74.08% | 74.52% | 74.26% | 73.97% | 73.56% | 73.09% | 73.49% | 74.29% | 74.56% | 75.25% | — | — | — | |||||||
Intuitive Surgical Inc. | 66.44% | 67.07% | 69.04% | 69.45% | 69.45% | 69.47% | 69.60% | 69.92% | 70.07% | 70.22% | 70.31% | 70.12% | 69.75% | 69.97% | 70.08% | 69.89% | 69.42% | 68.38% | 67.28% | 66.18% | — | — | — | |||||||
Medtronic PLC | 68.96% | 69.22% | 69.62% | 70.04% | 70.33% | 70.40% | 70.25% | 69.77% | 69.40% | 69.05% | 68.67% | 68.73% | 68.60% | 68.66% | 68.85% | 68.29% | 66.00% | 66.48% | 67.07% | 68.86% | — | — | — | |||||||
Stryker Corp. | 63.59% | 63.34% | 65.15% | 65.14% | 64.95% | 65.29% | 65.47% | 65.72% | 65.69% | 65.55% | 65.58% | 65.68% | 66.12% | 66.16% | 65.87% | 66.18% | 66.42% | 66.67% | 67.01% | 66.38% | — | — | — | |||||||
UnitedHealth Group Inc. | 25.83% | 25.95% | 23.52% | 23.19% | 22.92% | 22.89% | 23.15% | 23.33% | 23.36% | 23.33% | 23.28% | 22.98% | 23.09% | 23.12% | 22.99% | 23.13% | 22.35% | 22.20% | 22.73% | 23.22% | — | — | — |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
Gross profit margin = 100
× (Gross profitQ3 2020
+ Gross profitQ2 2020
+ Gross profitQ1 2020
+ Gross profitQ4 2019)
÷ (RevenuesQ3 2020
+ RevenuesQ2 2020
+ RevenuesQ1 2020
+ RevenuesQ4 2019)
= 100 × (4,331 + 3,377 + 2,740 + 3,035)
÷ (8,521 + 6,917 + 6,230 + 6,829)
= 47.31%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Thermo Fisher Scientific Inc.’s gross profit margin ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Operating Profit Margin
Thermo Fisher Scientific Inc., operating profit margin calculation (quarterly data)
Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 31, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Oct 1, 2016 | Jul 2, 2016 | Apr 2, 2016 | Dec 31, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Operating income | 2,426 | 1,391 | 906 | 1,232 | 946 | 1,496 | 920 | 1,148 | 912 | 937 | 786 | 958 | 636 | 752 | 622 | 753 | 541 | 638 | 518 | 690 | 563 | 596 | 487 | |||||||
Revenues | 8,521 | 6,917 | 6,230 | 6,829 | 6,272 | 6,316 | 6,125 | 6,507 | 5,920 | 6,078 | 5,853 | 6,047 | 5,116 | 4,990 | 4,765 | 4,953 | 4,491 | 4,535 | 4,295 | 4,653 | 4,123 | 4,271 | 3,919 | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Operating profit margin1 | 20.90% | 17.05% | 17.86% | 17.99% | 17.88% | 18.00% | 15.90% | 15.53% | 15.03% | 14.36% | 14.23% | 14.19% | 13.94% | 13.89% | 13.62% | 13.40% | 13.28% | 13.68% | 13.65% | 13.77% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 7.91% | 9.23% | 7.91% | 10.18% | 12.98% | 12.37% | 12.63% | 9.37% | 9.29% | 4.69% | 7.32% | 12.22% | 9.29% | 15.17% | 15.21% | 11.46% | 13.23% | 10.22% | 9.60% | 10.45% | — | — | — | |||||||
Boston Scientific Corp. | 0.79% | 6.58% | 10.41% | 14.14% | 15.66% | 16.19% | 16.50% | 15.33% | 15.57% | 15.74% | 14.33% | 14.20% | 12.53% | 12.36% | 6.04% | 5.33% | 0.44% | -7.68% | -0.76% | -4.37% | — | — | — | |||||||
Danaher Corp. | 17.61% | 17.37% | 18.01% | 18.25% | 17.77% | 17.61% | 17.41% | 17.11% | 17.27% | 17.23% | 16.69% | 16.48% | 15.73% | 15.69% | 16.09% | 16.29% | 16.51% | 16.27% | 16.81% | 16.87% | — | — | — | |||||||
Edwards Lifesciences Corp. | 19.62% | 18.36% | 27.45% | 26.38% | 20.01% | 19.81% | 20.15% | 20.10% | 30.15% | 29.89% | 30.46% | 31.89% | 28.80% | 28.75% | 27.30% | 25.35% | 25.16% | 25.01% | 25.39% | 25.49% | — | — | — | |||||||
Intuitive Surgical Inc. | 23.95% | 25.86% | 30.52% | 30.69% | 30.82% | 31.10% | 30.51% | 32.21% | 33.46% | 33.56% | 34.52% | 33.71% | 33.14% | 33.79% | 34.40% | 34.95% | 35.32% | 33.99% | 32.23% | 31.04% | — | — | — | |||||||
Medtronic PLC | 20.67% | 20.47% | 21.25% | 20.51% | 20.48% | 20.22% | 21.70% | 22.20% | 21.35% | 20.47% | 18.55% | 17.94% | 17.72% | 18.65% | 18.54% | 18.35% | 14.56% | 15.72% | 16.37% | 18.59% | — | — | — | |||||||
Stryker Corp. | 17.00% | 15.54% | 18.86% | 18.23% | 16.96% | 17.00% | 17.83% | 18.65% | 19.22% | 19.16% | 18.28% | 18.40% | 18.46% | 18.42% | 18.68% | 19.13% | 19.78% | 19.53% | 19.62% | 18.71% | — | — | — | |||||||
UnitedHealth Group Inc. | 9.55% | 9.89% | 8.12% | 8.19% | 8.02% | 7.97% | 7.88% | 7.71% | 7.70% | 7.68% | 7.67% | 7.60% | 7.37% | 7.26% | 7.11% | 7.03% | 6.78% | 6.64% | 6.87% | 7.05% | — | — | — |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
Operating profit margin = 100
× (Operating incomeQ3 2020
+ Operating incomeQ2 2020
+ Operating incomeQ1 2020
+ Operating incomeQ4 2019)
÷ (RevenuesQ3 2020
+ RevenuesQ2 2020
+ RevenuesQ1 2020
+ RevenuesQ4 2019)
= 100 × (2,426 + 1,391 + 906 + 1,232)
÷ (8,521 + 6,917 + 6,230 + 6,829)
= 20.90%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Thermo Fisher Scientific Inc.’s operating profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Net Profit Margin
Thermo Fisher Scientific Inc., net profit margin calculation (quarterly data)
Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 31, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Oct 1, 2016 | Jul 2, 2016 | Apr 2, 2016 | Dec 31, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income | 1,933 | 1,156 | 788 | 1,002 | 760 | 1,119 | 815 | 898 | 709 | 752 | 579 | 528 | 534 | 612 | 551 | 630 | 474 | 517 | 402 | 603 | 476 | 512 | 385 | |||||||
Revenues | 8,521 | 6,917 | 6,230 | 6,829 | 6,272 | 6,316 | 6,125 | 6,507 | 5,920 | 6,078 | 5,853 | 6,047 | 5,116 | 4,990 | 4,765 | 4,953 | 4,491 | 4,535 | 4,295 | 4,653 | 4,123 | 4,271 | 3,919 | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Net profit margin1 | 17.12% | 14.12% | 14.31% | 14.47% | 14.24% | 14.24% | 12.89% | 12.06% | 10.75% | 10.36% | 10.24% | 10.64% | 11.74% | 11.80% | 11.58% | 11.06% | 11.10% | 11.35% | 11.49% | 11.64% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 5.38% | 6.17% | 5.25% | 7.13% | 5.47% | 6.33% | 6.13% | 1.95% | 5.23% | 0.34% | 3.28% | 9.10% | 6.52% | 10.67% | 10.54% | 7.82% | 9.24% | 6.62% | 6.13% | 6.76% | — | — | — | |||||||
Boston Scientific Corp. | 36.65% | 39.24% | 39.75% | 43.78% | 10.49% | 13.85% | 18.08% | 17.01% | 6.93% | 5.48% | 1.21% | 1.15% | 9.55% | 9.04% | 5.07% | 4.14% | 0.99% | -4.34% | -0.47% | -3.20% | — | — | — | |||||||
Danaher Corp. | 18.05% | 18.35% | 18.13% | 16.80% | 13.47% | 13.11% | 12.45% | 13.33% | 14.07% | 13.84% | 13.56% | 13.60% | 13.36% | 12.63% | 13.41% | 15.13% | 13.72% | 18.39% | 17.92% | 16.33% | — | — | — | |||||||
Edwards Lifesciences Corp. | 18.18% | 17.21% | 24.71% | 24.08% | 18.64% | 18.29% | 20.03% | 19.40% | 19.61% | 18.50% | 16.25% | 16.99% | 22.47% | 22.16% | 20.85% | 19.22% | 19.24% | 19.26% | 19.78% | 19.85% | — | — | — | |||||||
Intuitive Surgical Inc. | 24.45% | 26.07% | 30.11% | 30.80% | 30.94% | 29.95% | 29.78% | 30.29% | 22.31% | 23.20% | 23.25% | 21.09% | 30.16% | 28.44% | 27.99% | 27.21% | 27.51% | 26.80% | 25.67% | 24.69% | — | — | — | |||||||
Medtronic PLC | 17.11% | 15.11% | 14.41% | 15.16% | 16.10% | 7.44% | 10.56% | 10.36% | 9.44% | 16.93% | 13.75% | 13.56% | 13.51% | 14.62% | 12.70% | 12.27% | 8.52% | 8.92% | 11.28% | 13.20% | — | — | — | |||||||
Stryker Corp. | 12.35% | 11.38% | 14.47% | 13.99% | 23.55% | 24.99% | 25.38% | 26.12% | 9.31% | 8.28% | 8.00% | 8.20% | 14.67% | 14.22% | 14.33% | 14.54% | 15.24% | 15.33% | 16.07% | 14.47% | — | — | — | |||||||
UnitedHealth Group Inc. | 6.66% | 6.94% | 5.63% | 5.76% | 5.61% | 5.55% | 5.49% | 5.33% | 5.75% | 5.58% | 5.43% | 5.28% | 4.41% | 4.23% | 4.03% | 3.81% | 3.64% | 3.52% | 3.64% | 3.72% | — | — | — |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
Net profit margin = 100
× (Net incomeQ3 2020
+ Net incomeQ2 2020
+ Net incomeQ1 2020
+ Net incomeQ4 2019)
÷ (RevenuesQ3 2020
+ RevenuesQ2 2020
+ RevenuesQ1 2020
+ RevenuesQ4 2019)
= 100 × (1,933 + 1,156 + 788 + 1,002)
÷ (8,521 + 6,917 + 6,230 + 6,829)
= 17.12%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Thermo Fisher Scientific Inc.’s net profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Return on Equity (ROE)
Thermo Fisher Scientific Inc., ROE calculation (quarterly data)
Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 31, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Oct 1, 2016 | Jul 2, 2016 | Apr 2, 2016 | Dec 31, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income | 1,933 | 1,156 | 788 | 1,002 | 760 | 1,119 | 815 | 898 | 709 | 752 | 579 | 528 | 534 | 612 | 551 | 630 | 474 | 517 | 402 | 603 | 476 | 512 | 385 | |||||||
Shareholders’ equity | 31,824 | 29,875 | 28,559 | 29,675 | 29,355 | 28,729 | 27,693 | 27,586 | 26,890 | 26,445 | 26,123 | 25,413 | 24,702 | 22,392 | 21,795 | 21,539 | 21,659 | 21,264 | 20,924 | 21,350 | 20,850 | 20,680 | 19,915 | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROE1 | 15.33% | 12.41% | 12.85% | 12.45% | 12.24% | 12.33% | 11.46% | 10.65% | 9.55% | 9.05% | 8.62% | 8.76% | 9.42% | 10.12% | 9.96% | 9.39% | 9.21% | 9.39% | 9.52% | 9.25% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 3.79% | 5.13% | 4.30% | 5.85% | 4.35% | 5.06% | 4.89% | 1.48% | 3.61% | 0.22% | 1.89% | 8.50% | 6.30% | 16.51% | 17.26% | 12.79% | 14.17% | 10.57% | 9.53% | 9.70% | — | — | — | |||||||
Boston Scientific Corp. | 23.80% | 25.53% | 31.06% | 33.87% | 11.24% | 14.81% | 19.46% | 19.15% | 8.08% | 6.73% | 1.59% | 1.48% | 11.11% | 10.89% | 6.17% | 5.15% | 1.25% | -5.55% | -0.56% | -3.78% | — | — | — | |||||||
Danaher Corp. | 9.70% | 9.56% | 10.53% | 9.94% | 7.63% | 7.69% | 7.66% | 9.40% | 9.98% | 9.81% | 9.39% | 9.45% | 9.39% | 8.95% | 9.68% | 11.10% | 10.76% | 14.00% | 14.47% | 14.17% | — | — | — | |||||||
Edwards Lifesciences Corp. | 18.86% | 19.37% | 28.40% | 25.24% | 20.28% | 20.71% | 22.20% | 23.00% | 21.19% | 20.75% | 17.25% | 19.74% | 23.55% | 24.36% | 23.94% | 21.74% | 20.50% | 21.38% | 22.38% | 19.77% | — | — | — | |||||||
Intuitive Surgical Inc. | 11.38% | 13.00% | 16.30% | 16.69% | 16.93% | 16.65% | 16.33% | 16.89% | 12.68% | 13.68% | 13.97% | 13.97% | 18.21% | 18.05% | 18.88% | 12.74% | 13.03% | 13.09% | 13.22% | 13.63% | — | — | — | |||||||
Medtronic PLC | 10.26% | 9.23% | 8.78% | 9.25% | 9.87% | 4.56% | 6.30% | 6.12% | 5.59% | 9.75% | 8.12% | 8.01% | 8.03% | 8.45% | 7.18% | 6.80% | 4.79% | 4.43% | 4.97% | 5.03% | — | — | — | |||||||
Stryker Corp. | 13.52% | 12.55% | 16.50% | 16.26% | 27.82% | 29.72% | 30.12% | 30.29% | 12.54% | 11.42% | 11.06% | 10.23% | 17.06% | 16.94% | 17.41% | 17.25% | 17.78% | 17.64% | 18.36% | 16.91% | — | — | — | |||||||
UnitedHealth Group Inc. | 25.65% | 26.87% | 24.14% | 24.02% | 24.25% | 24.46% | 24.39% | 23.19% | 25.12% | 24.56% | 23.60% | 22.10% | 19.04% | 18.79% | 18.08% | 18.33% | 17.40% | 16.98% | 17.09% | 17.18% | — | — | — |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
ROE = 100
× (Net incomeQ3 2020
+ Net incomeQ2 2020
+ Net incomeQ1 2020
+ Net incomeQ4 2019)
÷ Shareholders’ equity
= 100 × (1,933 + 1,156 + 788 + 1,002)
÷ 31,824 = 15.33%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Thermo Fisher Scientific Inc.’s ROE deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Return on Assets (ROA)
Thermo Fisher Scientific Inc., ROA calculation (quarterly data)
Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 31, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Oct 1, 2016 | Jul 2, 2016 | Apr 2, 2016 | Dec 31, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income | 1,933 | 1,156 | 788 | 1,002 | 760 | 1,119 | 815 | 898 | 709 | 752 | 579 | 528 | 534 | 612 | 551 | 630 | 474 | 517 | 402 | 603 | 476 | 512 | 385 | |||||||
Total assets | 64,061 | 61,593 | 58,688 | 58,381 | 56,729 | 57,970 | 55,596 | 56,232 | 55,078 | 55,403 | 56,580 | 56,669 | 55,985 | 46,514 | 46,214 | 45,908 | 48,011 | 42,253 | 42,953 | 40,889 | 41,147 | 41,774 | 41,857 | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROA1 | 7.62% | 6.02% | 6.25% | 6.33% | 6.33% | 6.11% | 5.71% | 5.22% | 4.66% | 4.32% | 3.98% | 3.93% | 4.16% | 4.87% | 4.70% | 4.40% | 4.16% | 4.73% | 4.64% | 4.83% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 1.69% | 2.01% | 1.76% | 2.38% | 1.79% | 2.05% | 1.98% | 0.58% | 1.43% | 0.08% | 0.73% | 2.92% | 2.13% | 5.45% | 5.38% | 3.81% | 4.37% | 3.09% | 2.64% | 2.59% | — | — | — | |||||||
Boston Scientific Corp. | 12.01% | 12.93% | 14.24% | 15.38% | 4.07% | 5.74% | 7.55% | 7.96% | 3.29% | 2.66% | 0.58% | 0.55% | 4.52% | 4.29% | 2.42% | 1.92% | 0.46% | -1.93% | -0.20% | -1.32% | — | — | — | |||||||
Danaher Corp. | 5.05% | 4.86% | 4.74% | 4.85% | 4.03% | 4.64% | 4.67% | 5.54% | 5.79% | 5.55% | 5.41% | 5.34% | 5.20% | 4.82% | 5.09% | 5.64% | 6.04% | 6.81% | 7.33% | 6.96% | — | — | — | |||||||
Edwards Lifesciences Corp. | 11.68% | 11.58% | 18.23% | 16.14% | 12.97% | 13.01% | 13.99% | 13.57% | 11.96% | 11.55% | 9.61% | 10.25% | 13.57% | 13.94% | 13.74% | 12.63% | 12.71% | 13.04% | 13.35% | 12.19% | — | — | — | |||||||
Intuitive Surgical Inc. | 9.92% | 11.24% | 14.02% | 14.17% | 14.39% | 14.18% | 13.93% | 14.37% | 10.88% | 11.70% | 11.95% | 11.46% | 15.99% | 15.55% | 16.21% | 11.34% | 11.69% | 11.73% | 11.84% | 12.00% | — | — | — | |||||||
Medtronic PLC | 5.73% | 5.13% | 4.84% | 5.16% | 5.54% | 2.56% | 3.53% | 3.40% | 2.93% | 5.31% | 4.10% | 4.04% | 4.07% | 4.31% | 3.70% | 3.55% | 2.37% | 2.21% | 2.51% | 2.51% | — | — | — | |||||||
Stryker Corp. | 5.44% | 5.09% | 7.35% | 6.90% | 12.85% | 13.47% | 13.58% | 13.05% | 5.60% | 5.01% | 4.60% | 4.60% | 8.28% | 7.98% | 8.23% | 8.06% | 8.22% | 7.82% | 8.22% | 8.86% | — | — | — | |||||||
UnitedHealth Group Inc. | 8.76% | 8.88% | 7.27% | 7.96% | 7.68% | 7.77% | 7.83% | 7.87% | 8.32% | 7.67% | 7.21% | 7.59% | 6.14% | 5.87% | 5.53% | 5.71% | 5.30% | 5.17% | 5.10% | 5.22% | — | — | — |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
ROA = 100
× (Net incomeQ3 2020
+ Net incomeQ2 2020
+ Net incomeQ1 2020
+ Net incomeQ4 2019)
÷ Total assets
= 100 × (1,933 + 1,156 + 788 + 1,002)
÷ 64,061 = 7.62%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Thermo Fisher Scientific Inc.’s ROA deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |